• News
  • BioTech

Triphase's proteasome inhibitor posts promising results

Triphase Accelerator Corp., a private drug development accelerator with offices in San Diego and Toronto, announced preclinical study results demonstrating that the combination of marizomib, Triphase’s highly-differentiated proteasome inhibitor, and pomalidomide (Pomalyst) was synergistic in killing multiple myeloma cells.

To continue reading, subscribe now
log in to your account
User Response
0 UserComments
Subscribe Today!